Prevail

Prospective Randomized EVAluation of Warfarin Therapy In Atrial Fibrillation Patients Versus WATCHMAN LAA Closure Technology (PREVAIL)

Prevail [NCT01182441]

Description: Prospective Randomized EVAluation of Warfarin Therapy In Atrial Fibrillation Patients Versus WATCHMAN LAA Closure Technology (PREVAIL)

Device: Atritech Watchman Left atrial appendage (LAA) closure device; Control: Warfarin

Primary Investigator: Gupta

Drug/Device Information
Watchman LAA closure device vs long term warfarin in patients with AF
Endpoint is the occurrence of stroke, cardiovascular death and systemic embolism.
Atritech
Major Inclusion and Exclusion
Non valvular AF and eligible for warfarin
Able to be off warfarin if LAA is sealed
CHADS score of 2 or greater
Must be Medicare patients